Non-Small Cell Lung Cancer Therapeutics Market Size, Share, Growth, Trends, and Forecast by 2031

MARKET INTRODUCTION

About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as NSCLC because their treatment and prognoses (outlook) are often similar.

MARKET DYNAMICS

The non-small cell lung cancer therapeutics market is driving due to the increasing patient population, expected entry of several drugs, and rising investment by industry players in R&D of NSCLC therapy. However, pricing pressure may impede the growth.

MARKET SCOPE

The "Non-Small Cell Lung Cancer Therapeutics Market Analysis to 2031" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of non-small cell lung cancer therapeutics market with detailed market segmentation by therapy and cancer type. The non-small cell lung cancer therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in non-small cell lung cancer therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The non-small cell lung cancer therapeutics market is segmented on the basis by therapy and cancer type. On the basis of therapy, the market is categorized as target therapy, immunotherapy, and chemotherapy. On the basis of cancer type, the market is categorized as adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the non-small cell lung cancer therapeutics market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The non-small cell lung cancer therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting non-small cell lung cancer therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the non-small cell lung cancer therapeutics market in these regions.

MARKET PLAYERS

The report covers key developments in the non-small cell lung cancer therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from non-small cell lung cancer therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for non-small cell lung cancer therapeutics in the global market. Below mentioned is the list of few companies engaged in the non-small cell lung cancer therapeutics market.

The report also includes the profiles of key players in non-small cell lung cancer therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•  GlaxoSmithKline plc
  
•  Novartis
  
•  AstraZeneca
  
•  Eli Lilly and Company
  
•  Pfizer Inc.
  
•  F. Hoffmann-La Roche Ltd
  
•  Bristol-Myers Squibb
  
•  Takeda
  
•  Merck Sharp
  
•  Boehringer Ingelheim
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Non-Small Cell Lung Cancer Therapeutics Report Scope